(MedPage Today) — Etranacogene dezaparvovec (Hemgenix), the only commercially available gene therapy for hemophilia B, is temporarily unavailable, according to maker CSL Behring.
In a letter addressed to the hemophilia B community, the company…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
